Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study (KL002)
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of KL002 Injection in the Striatal Putamen Region for Patients With Mid-to-Late Stage Primary Parkinson's Disease
Evaluate the safety and tolerability of stereotactic injection of KL002 into the putamen of patients with advanced primary PD.
研究概览
详细说明
This is an open-label, non-randomized, phase 1/2a single ascending dose study, consisting of Dose Escalation and Dose Expansion parts, to evaluate the safety, tolerability, and efficacy of KL002 in patients with advanced primary Parkinson's disease. Eligible subjects will enter the dose escalation part of the study, receive a single stereotactic intraputaminal administration of KL002, and be followed for 52 weeks in the core study and up to 5 years total in long-term follow-up (LTFU)with safety and efficacy assessments.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:jun Liu, Professor, Chief Physician, MD, Ph D
- 电话号码:+86-021-64370045
- 邮箱:jly0520@hotmail.com
学习地点
-
-
-
Shanghai、中国、200025
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
接触:
- Jun Liu, Professor, Chief Physician, MD, Ph D
- 电话号码:+86-021-64370045
- 邮箱:jly0520@hotmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Clinically diagnosed primary PD
- Males or females ≥ 40 and ≤ 75 years old
- History of Parkinson's disease diagnosis ≥ 5 years
- Regularly take stable equivalent doses of dopaminergic drugs (including levodopa) for at least 4 weeks before the screening period
- Good compliance and regular follow-up
Exclusion Criteria:
- Atypical or secondary Parkinson's syndrome
- Have surgical contraindications or have undergone brain surgery in the past
- Any indications of elevated intracranial pressure evaluated by investigator
- Abnormal liver and kidney function
- Prior severe allergic reactions or allergic to contrast agents or unable to accept surgical anesthesia
- Any type of prior gene or cell therapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:low dose group
Putamen stereotactic injection of low dose of KL002 |
KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes |
|
实验性的:high dose group
Putamen stereotactic injection of high dose of KL002 |
KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adverse event (AE) incidence
大体时间:From administration of KL002 to the end of the follow-up within 52 weeks
|
To evaluate AEs by CTCAE 6.0 |
From administration of KL002 to the end of the follow-up within 52 weeks
|
|
The incidence rate of DLT events
大体时间:within 4 weeks
|
Determined by the Safety Data Review Committee |
within 4 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Assessment of motor function
大体时间:within 52 weeks
|
Determined by MDS-UPDRS III. The highest score is 56 points, and the lower the score, the better the recovery situation. |
within 52 weeks
|
|
Assessment of dyskinesia
大体时间:within 52 weeks
|
Determined by UDysRS. The highest score is 104 points, and the lower the score, the better the recovery situation. |
within 52 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.